These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 12507560

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ.
    Nature; 1999 May 20; 399(6733):271-5. PubMed ID: 10353251
    [Abstract] [Full Text] [Related]

  • 4. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA, Ohh M.
    Am J Nephrol; 2004 May 20; 24(1):1-13. PubMed ID: 14654728
    [Abstract] [Full Text] [Related]

  • 5. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.
    J Biol Chem; 2000 Aug 18; 275(33):25733-41. PubMed ID: 10823831
    [Abstract] [Full Text] [Related]

  • 6. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER.
    Hum Mol Genet; 2001 May 01; 10(10):1029-38. PubMed ID: 11331613
    [Abstract] [Full Text] [Related]

  • 7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH.
    Oncogene; 2000 Nov 16; 19(48):5435-43. PubMed ID: 11114720
    [Abstract] [Full Text] [Related]

  • 8. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG.
    Hum Mol Genet; 2001 May 01; 10(10):1019-27. PubMed ID: 11331612
    [Abstract] [Full Text] [Related]

  • 9. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
    Kim W, Kaelin WG.
    Curr Opin Genet Dev; 2003 Feb 01; 13(1):55-60. PubMed ID: 12573436
    [Abstract] [Full Text] [Related]

  • 10. The von Hippel-Lindau tumor suppressor gene.
    Kondo K, Kaelin WG.
    Exp Cell Res; 2001 Mar 10; 264(1):117-25. PubMed ID: 11237528
    [Abstract] [Full Text] [Related]

  • 11. Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product.
    Pereira T, Zheng X, Ruas JL, Tanimoto K, Poellinger L.
    J Biol Chem; 2003 Feb 28; 278(9):6816-23. PubMed ID: 12468553
    [Abstract] [Full Text] [Related]

  • 12. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
    Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ.
    Science; 2001 Apr 20; 292(5516):468-72. PubMed ID: 11292861
    [Abstract] [Full Text] [Related]

  • 13. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.
    Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293
    [Abstract] [Full Text] [Related]

  • 14. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER.
    Oncogene; 2005 Jun 30; 24(28):4549-58. PubMed ID: 15824735
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    Tanimoto K, Makino Y, Pereira T, Poellinger L.
    EMBO J; 2000 Aug 15; 19(16):4298-309. PubMed ID: 10944113
    [Abstract] [Full Text] [Related]

  • 16. The von Hippel-Lindau tumor suppressor protein.
    Ivan M, Kaelin WG.
    Curr Opin Genet Dev; 2001 Feb 15; 11(1):27-34. PubMed ID: 11163147
    [Abstract] [Full Text] [Related]

  • 17. The pVHL-hIF-1 system. A key mediator of oxygen homeostasis.
    Maxwell PH, Pugh CW, Ratcliffe PJ.
    Adv Exp Med Biol; 2001 Feb 15; 502():365-76. PubMed ID: 11950150
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.
    Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, Jelkmann W, Jaakkola P, Metzen E.
    Biochem J; 2004 Aug 01; 381(Pt 3):761-7. PubMed ID: 15104534
    [Abstract] [Full Text] [Related]

  • 19. Molecular targets from VHL studies into the oxygen-sensing pathway.
    Maynard MA, Ohh M.
    Curr Cancer Drug Targets; 2005 Aug 01; 5(5):345-56. PubMed ID: 16101382
    [Abstract] [Full Text] [Related]

  • 20. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP.
    Sang N, Fang J, Srinivas V, Leshchinsky I, Caro J.
    Mol Cell Biol; 2002 May 01; 22(9):2984-92. PubMed ID: 11940656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.